Myriad Genetics Net Worth
Myriad Genetics Net Worth Breakdown | MYGN |
Myriad Genetics Net Worth Analysis
Myriad Genetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Myriad Genetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Myriad Genetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Myriad Genetics' net worth analysis. One common approach is to calculate Myriad Genetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Myriad Genetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Myriad Genetics' net worth. This approach calculates the present value of Myriad Genetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Myriad Genetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Myriad Genetics' net worth. This involves comparing Myriad Genetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Myriad Genetics' net worth relative to its peers.
Enterprise Value |
|
To determine if Myriad Genetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Myriad Genetics' net worth research are outlined below:
| Myriad Genetics generated a negative expected return over the last 90 days | |
| Myriad Genetics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 753.2 M. Net Loss for the year was (263.3 M) with profit before overhead, payroll, taxes, and interest of 476.4 M. | |
| Myriad Genetics currently holds about 205.1 M in cash with (110.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.54. | |
| Myriad Genetics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from forbes.com: The Myriad Leader Shifting The Way We Think About Leadership |
Myriad Genetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Myriad Genetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Myriad Genetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Myriad Genetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Myriad Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Myriad Genetics backward and forwards among themselves. Myriad Genetics' institutional investor refers to the entity that pools money to purchase Myriad Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.4 M | Sei Investments Co | 2024-06-30 | 2.4 M | Geode Capital Management, Llc | 2024-09-30 | 2.2 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.4 M | Glenview Capital Management Llc | 2024-09-30 | 1.3 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 967.2 K | Blackrock Inc | 2024-06-30 | 15.2 M | Vanguard Group Inc | 2024-09-30 | 10.3 M |
Follow Myriad Genetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.41 B.Market Cap |
|
Project Myriad Genetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.18) | |
| Return On Capital Employed | (0.10) | (0.10) | |
| Return On Assets | (0.08) | (0.08) | |
| Return On Equity | (0.13) | (0.11) |
When accessing Myriad Genetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Myriad Genetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Myriad Genetics' profitability and make more informed investment decisions.
Evaluate Myriad Genetics' management efficiency
Myriad Genetics has return on total asset (ROA) of (0.0535) % which means that it has lost $0.0535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.164) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -0.18. In addition to that, Return On Capital Employed is likely to grow to -0.1. At this time, Myriad Genetics' Non Current Assets Total are very stable compared to the past year. As of the 26th of November 2024, Non Currrent Assets Other is likely to grow to about 16.2 M, while Total Assets are likely to drop about 670.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.89 | 5.38 | |
| Tangible Book Value Per Share | 2.45 | 2.54 | |
| Enterprise Value Over EBITDA | (16.69) | (15.85) | |
| Price Book Value Ratio | 1.52 | 1.44 | |
| Enterprise Value Multiple | (16.69) | (15.85) | |
| Price Fair Value | 1.52 | 1.44 | |
| Enterprise Value | 1.1 B | 790.3 M |
At Myriad Genetics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 1.7646 | Revenue 823.6 M | Quarterly Revenue Growth 0.112 | Revenue Per Share 9.205 | Return On Equity (0.16) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Myriad Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Myriad Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Myriad Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Myriad Genetics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 11th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Myriad Genetics Earnings per Share Projection vs Actual
Myriad Genetics Corporate Management
| Justin Hunter | Interim Secretary | Profile | |
| Nicole Lambert | Chief Officer | Profile | |
| Jennifer Fox | Chief Officer | Profile | |
| Clivetty Martinez | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.